Company Profile
Capricor Therapeutics Stock Price, News & Catalysts
- Ticker:
- CAPR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.94 USD (-5.60%)
Close
Last updated: October 1, 2026
1.58B USD
Market cap
Why the stock is moving
The latest monitored company update is “Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress.” The corresponding closing-price reaction is not yet available.
Company overview
Cell Therapy for Duchenne Muscular Dystrophy
Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.
Deramiocel
The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling.
HOPE-3 Evidence
The Phase 3 HOPE-3 study met its primary upper-limb function endpoint and all type I error-controlled secondary endpoints.
Future catalysts
- FDA decision on the deramiocel BLA for Duchenne muscular dystrophy.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Capricor Therapeutics (CAPR)?
Capricor Therapeutics (CAPR) most recently closed at 8.94 USD, a -5.60% move versus the previous session.
What is the market cap of Capricor Therapeutics (CAPR)?
Capricor Therapeutics currently has a market capitalization of 1.58B USD on BioPharmSignal.
What does Capricor Therapeutics do?
Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The Phase 3 HOPE-3 study...
On which exchange is CAPR stock listed?
Capricor Therapeutics (CAPR) is associated with NASDAQ, United States, Biopharma.
What is HOPE-3?
HOPE-3 Evidence The Phase 3 HOPE-3 study met its primary upper-limb function endpoint and all type I error-controlled secondary endpoints.
Which conditions is Capricor Therapeutics targeting with HOPE-3?
Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The Phase 3 HOPE-3 study...
How does Capricor Therapeutics describe recent progress with HOPE-3?
FDA decision on the deramiocel BLA for Duchenne muscular dystrophy.
What is Cell?
Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.